BioCardia (BCDA) Stock Price, News & Analysis

Company Overview

BioCardia, Inc. is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System. The Helix system is designed to facilitate precise, minimally invasive delivery of cells and biologics into viable myocardium. CardiAMP is an autologous bone marrow-derived progenitor cell therapy under investigation for its potential to improve cardiac function in patients with ischemic heart failure. Both platforms have secured investigational device exemptions from the U.S. Food and Drug Administration and are being evaluated in multi-center clinical trials.

Founded in the mid-2000s and headquartered in the San Francisco Bay Area, BioCardia has assembled a leadership team with deep expertise in interventional cardiology, regenerative medicine, and medical device development. Gary S. Margulies, M.D., serves as President and Chief Executive Officer, guiding the company’s clinical programs and strategic partnerships. BioCardia collaborates with academic medical centers and clinical research organizations across the United States to advance its pipeline and ultimately bring new therapeutic options to patients suffering from heart disease.

Key Stats

• Today's Range: $0.79 to $0.82
• 50-Day Range: $0.77 to $1.24
• 52-Week Range: $0.75 to $2.29
• Volume: 125,505 shs
• Average Volume: 353,373 shs
• Market Capitalization: $9.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Reduce

BioCardia Stock Analysis - MarketRank™

BioCardia scored higher than 54% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Reduce

Consensus Rating

BioCardia has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 2 sell ratings.

Upside Potential

BioCardia has a consensus price target of $25.00, representing about 2,933.2% upside from its current price of $0.82.

Amount of Analyst Coverage

BioCardia has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioCardia are expected to grow in the coming year, from ($0.76) to ($0.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioCardia is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioCardia is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioCardia has a P/B Ratio of 10.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.29% of the float of BioCardia has been sold short.

Short Interest Ratio / Days to Cover

BioCardia has a short interest ratio ("days to cover") of 2.63, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioCardia has recently increased by 261.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioCardia does not currently pay a dividend.

Dividend Growth

BioCardia does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for BioCardia this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for BCDA on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.

MarketBeat Follows

8 people have added BioCardia to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 4.4 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of BioCardia in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $137,212.00 in company stock, which represents 1.4629% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, BioCardia insiders have bought more of their company's stock than they have sold. Specifically, they have bought $137,212.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

17.40% of the stock of BioCardia is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

20.57% of the stock of BioCardia is held by institutions.

Company Calendar

• Last Earnings: 5/15/2026
• Today: 8/02/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:BCDA
• CIK: 925741
• Web: www.biocardia.com
• Phone: (650) 226-0120
• Fax: 310-861-5299
• Employees: 40
• Year Founded: 2002

Price Target and Rating

• Average Price Target for BioCardia: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2,933.2%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$8.23 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,456.14%
• Return on Assets: -232.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.41
• Quick Ratio: 0.41

Sales & Book Value

• Annual Sales: $60 thousand
• Price / Sales: 156.32
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.08 per share
• Price / Book: 10.30

Miscellaneous

• Outstanding Shares: 11,380,000
• Free Float: 9,396,000
• Market Cap: $9.38 million
• Optionable: Optionable
• Beta: 0.44